ANI Pharmaceuticals vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

ANI Pharmaceuticals Inc (ANIP)

Q3 202613 Jul – 15 Aug 2026

▼3▲1

ANI's Q2 revenue beat but Cortrophin guidance cut and legal loss weigh

Record Q2 revenue and $100M buyback ANI reported record Q2 2026 revenue of $266 million, up 25.9% from a year ago, and adjusted earnings per share of $2.21 beat expectations. The board also authorized a $100 million share buyback through 2029, which supports the stock by returning cash to shareholders.
This is the core positive financial result that drove the quarter and shows the company's underlying growth.
Cortrophin guidance cut despite volume growth ANI lowered its 2026 Cortrophin Gel revenue outlook to $520-$540 million from $540-$575 million, and Q2 Cortrophin sales of $117.1 million missed the $120.4 million consensus. This signals weaker-than-expected demand for a key drug and pressures the stock.
The guidance cut is the main negative event of the period and directly explains why the stock fell after earnings.
Full-year guidance misses, stock drops 9.1% Even though Q2 revenue beat estimates by 2.4%, ANI's full-year revenue guidance slightly missed expectations, making it the weakest guidance among four generic drug peers. The stock fell 9.1% to $75.12, reflecting investor disappointment with the forward outlook.
This captures the market reaction and the relative weakness versus peers, which is central to why the stock moved.
Legal setback in CG Oncology royalty dispute A Delaware court denied ANI's motions for a new trial and judgment in its dispute with CG Oncology over a 5% royalty on future sales of cretostimogene grenadenorepvec. ANI will appeal to the Delaware Supreme Court, but the loss threatens a potential royalty revenue stream and adds uncertainty.
This is a distinct negative legal development that could affect future royalty income and investor sentiment.

July 202613 Jul – 15 Aug 2026

▼3▲1

ANI's Q2 revenue beat but Cortrophin guidance cut and legal loss weigh

Record Q2 revenue and $100M buyback ANI reported record Q2 2026 revenue of $266 million, up 25.9% from a year ago, and adjusted earnings per share of $2.21 beat expectations. The board also authorized a $100 million share buyback through 2029, which supports the stock by returning cash to shareholders.
This is the core positive financial result that drove the quarter and shows the company's underlying growth.
Cortrophin guidance cut despite volume growth ANI lowered its 2026 Cortrophin Gel revenue outlook to $520-$540 million from $540-$575 million, and Q2 Cortrophin sales of $117.1 million missed the $120.4 million consensus. This signals weaker-than-expected demand for a key drug and pressures the stock.
The guidance cut is the main negative event of the period and directly explains why the stock fell after earnings.
Full-year guidance misses, stock drops 9.1% Even though Q2 revenue beat estimates by 2.4%, ANI's full-year revenue guidance slightly missed expectations, making it the weakest guidance among four generic drug peers. The stock fell 9.1% to $75.12, reflecting investor disappointment with the forward outlook.
This captures the market reaction and the relative weakness versus peers, which is central to why the stock moved.
Legal setback in CG Oncology royalty dispute A Delaware court denied ANI's motions for a new trial and judgment in its dispute with CG Oncology over a 5% royalty on future sales of cretostimogene grenadenorepvec. ANI will appeal to the Delaware Supreme Court, but the loss threatens a potential royalty revenue stream and adds uncertainty.
This is a distinct negative legal development that could affect future royalty income and investor sentiment.

Latest13 Jul – 15 Aug 2026

▼3▲1

ANI's Q2 revenue beat but Cortrophin guidance cut and legal loss weigh

Record Q2 revenue and $100M buyback ANI reported record Q2 2026 revenue of $266 million, up 25.9% from a year ago, and adjusted earnings per share of $2.21 beat expectations. The board also authorized a $100 million share buyback through 2029, which supports the stock by returning cash to shareholders.
This is the core positive financial result that drove the quarter and shows the company's underlying growth.
Cortrophin guidance cut despite volume growth ANI lowered its 2026 Cortrophin Gel revenue outlook to $520-$540 million from $540-$575 million, and Q2 Cortrophin sales of $117.1 million missed the $120.4 million consensus. This signals weaker-than-expected demand for a key drug and pressures the stock.
The guidance cut is the main negative event of the period and directly explains why the stock fell after earnings.
Full-year guidance misses, stock drops 9.1% Even though Q2 revenue beat estimates by 2.4%, ANI's full-year revenue guidance slightly missed expectations, making it the weakest guidance among four generic drug peers. The stock fell 9.1% to $75.12, reflecting investor disappointment with the forward outlook.
This captures the market reaction and the relative weakness versus peers, which is central to why the stock moved.
Legal setback in CG Oncology royalty dispute A Delaware court denied ANI's motions for a new trial and judgment in its dispute with CG Oncology over a 5% royalty on future sales of cretostimogene grenadenorepvec. ANI will appeal to the Delaware Supreme Court, but the loss threatens a potential royalty revenue stream and adds uncertainty.
This is a distinct negative legal development that could affect future royalty income and investor sentiment.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.